2022 Summit on Cancer Health Disparities

Seattle, WA US
April 29, 2022 to May 1, 2022

Learning Objectives

At the conclusion of the activity, participants will be able to:

  1. Identify drivers of cancer health disparities and review their impact on patients along the cancer continuum.
  2. State the financial and physical barriers, review strategies to navigate these factors to optimize management of patients with cancer.
  3. Incorporate evidence-based strategies to minimize the impact of specific drivers of inequity in the management of patients with cancer.
  4. Describe challenges and develop novel approaches to improve participation of underrepresented communities in clinical trials.

ABSTRACT SUBMISSION INFORMATION

ABSTRACT SUBMISSION DEADLINE: January 10, 2022 11:59 PM Pacific Time

 

We will accept abstracts in the following categories. 

Please select a category that fits the submission best when submitting the abstract.

  • Technology
  • Tumor biology
  • Precision oncology
  • Epidemiology
  • Screening
  • Health policy
  • Survivorship
  • Quality improvement
  • Database analysis
  • Encore abstracts: The abstract committee will accept encore clinical trials abstracts for this conference. Submissions with additional data that supplement the previous presentation will be preferred. Authors should provide information regarding the original presentation, including the name of the meeting where the abstract was originally presented.

Course summary
Available credit: 
  • 14.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 14.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 14.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 14.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 14.00 Contact Hours.
Course opens: 
09/21/2021
Course expires: 
09/01/2022
Event starts: 
04/29/2022 - 7:52am PDT
Event ends: 
05/01/2022 - 5:00pm PDT
Cost:
$450.00

Conference Chairs: David Aboulafia, MD, Edith P. Mitchell, MD, and Hannah Linden, MD, FACP

All times listed below are in Pacific Standard Time.

April 29, 2022

2 PM to 3 PM - Registration/Check-in, Exhibits

3:00 PM – 3:15 PM PST: Welcome


Session 1: 3:15 PM – 4:15 PM PST: Access to insurance and cancer disparities

Moderator: Hannah Linden, MD, FACP

3:15 - 3:30 PM PST: Access to insurance and access to cancer care - Amy Davidoff, PhD, MS

3:30 - 3:45 PM PST: ACA and access to cancer care - J. Richard Goss, MD, MPH, FACP

3:45 - 4:00 PM PST: Experience from a county hospital - Hannah Linden, MD, FACP

4:00 - 4:15 PM PST: Panel discussion / Q&A


Session 2: 4:15 PM – 5:15 PM PST: Cancer care disparities – training the next generation

Moderator: Chandrikha Chandrasekharan, MBBS

4:15 - 4:25 PM PST: Career in cancer care disparities - Narjust Duma, MD

4:25 - 4:35 PM PST: Funding opportunities for disparities research - Edith Mitchell, MD

4:35 - 5:15 PM PST: Panel discussion - Manali Indravadan Patel, MD, MPH, MS, Molly Tokaz, MD, Lisa Tachiki, MD



5:15 PM to 6:30 PM PST: Roundtable discussion - Access to care by practice setting

Moderator: Rachna Shroff, MD

Keynote Speech: Ana Maria Lopez, MD, MPH, MACP, FRCP

Panelists: Shailender Bhatia, MD, Joseph Rosales, MD, Michael Wagner, MD, Sibel Blau, MD


April 30, 2022

Session 1: 08:00 AM to 09:45 AM PST: Technology and cancer disparities

Moderator: Jack West, MD

8:00 - 8:15 AM PST: Telemedicine for cancer care after the COVID-19 pandemic: lessons learned - Jack West, MD

8:15 - 8:30 AM PST: Mitigating disparities potentially magnified by telemedicine: Addressing "Techquity" - Joy Feliciano, MD

8:30 - 8:45 AM PST: Project ECHO and delivering global oncology - Ellen Baker, MD, MPH

8:45 - 9:00 AM PST: Panel discussion, Q/A on telemedicine addressing or worsening disparities 

9:00 - 9:15 AM PST: Asynchronous integration of an oncology subspecialist with local delivery of cancer care: The AccessHope experience - Afsaneh Barzi, MD, PhD

9:15 - 9:30 AM PST: Virtual tumor boards to bring subspecialist care beyond tertiary care centers - Ghassan Abou-Alfa, MD, MBA

9:30 - 9:45 AM PST: Panel discussion, Q/A on models for overcoming geographic barriers to increasingly complex oncology delivery


9:45 - 10:15 AM PST: Break 


Session 2: 10:15 AM to 12:00 PM PST: Breast Cancer Disparities Session – sponsored by BCRF

Moderator: Julie Gralow, MD 

10:15 - 10:30 AM PST: Lancet Commission on Women and Cancer - Ophira Ginsburg, MD

10:30 - 10:45 AM PST: WHO Global Breast Cancer Initiative - Ben Anderson, MD

10:45 - 11:00 AM PST: Overcoming Racial, Ethnic, and Socioeconomic Disparities in Breast Cancer Care in the US - Edith Mitchell, MD

11:00 - 11:15 AM PST: University of Washington Equity Initiative - Rachel Yung, MD

11:15 - 12:00 PM PST: Panel Discussion - Bridgette Hempstead


12:00 - 01:00 PM PST: Lunch 


Session 3: 1:00 PM to 2:15 PM PST: Professional Societies’ initiatives in improving cancer health disparities

Moderator: Edith Mitchell, MD

1:00 - 1:30 PM PST: Society President or representative presentations

  • ASCO's efforts in improving access to cancer care - Everett Vokes, MD, FASCO
  • ASCP's efforts in improving access to cancer care - Danny A. Milner, Jr, MD, MSc(Epi), FASCP
  • EONS' efforts in improving access to cancer care - Johan deMunter, EONS President
  • ASTRO’S efforts in improving access to cancer care – Geraldine Jacobson, MD, MPH, MBA, FASTRO
  • NCCN'S efforts in improving access to cancer care - Robert W. Carlson, MD 

1:30 - 2:15 PM PST: Panel discussion 


2:15 PM to 2:45 PM PST: Break


Session 4: 2:45 PM to 4:15 PM PST: Cancer Health Disparities in the LGBTQ population

Moderator: David Aboulafia, MD

2:45 - 3:05 PM PST: Anal cancer screening among people living with HIV: Lessons from the ANCHOR study - Joel Palefsky, MD 

3:05 - 3:25 PM PST: Cultural barriers to equity and cancer disparities among sexual and gender minorities - Matthew Schabath, PhD

3:25 - 3:45 PM PST: Cancer screening among women living with HIV - Liz Chiao, MD

3:45 - 4:15 PM PST: Panel discussion - Bakari Salim AIDS Malignancy Community Global CAB and Michael Louella, University of Washington AIDS Clinical Trial Unit Outreach Coordinator 


6:00 - 9:00 PM PST: Gala dinner


May 01, 2022

Session 1: 8:00 AM to 9:15 AM PST: Global Oncology 

Moderators: Aparna Parikh, MD, MS & Bhawna Sirohi, MBBS, FRCP

8:00 - 8:15 AM PST: The promise of Universal Health Coverage (UHC) for global cancer: moving from challenges to solutions - Professor Richard Sullivan, PhD

8:15 - 8:30 AM PST: Levelling the field in cancer research to control global cancer burden - Nazik Hammad, MD, MSc, MEHP, FACP

8:30 - 8:45 AM PST: Founding of cancer care and research institute in Jamaica - Dingle Spence, BSc, MBBS, DMRT, Dip Pall. Med, FRCR

8:45 - 9:15 AM PST: Panel discussion - Manoj P. Menon, MD, MPH


9:15 - 9:45 AM  PST: Break & Abstract Session 1

9:15 - 9:21 AM - Poster: 

  • A Global Community Advisory Board (GCAB) to enhance clinical research studies in the AIDS Malignancy Consortium (AMC)
  • An Evaluation of Health Disparities Among Breast Cancer Patients and the Relationship to Emergency Department Utilization

9:21 - 9:27 AM - Poster: 

  • A Methodology to Quality Improvement in Patient Navigation, Access to Care, and Patient Education in Rural and Urban Cancer Centers
  • Addressing Latinx CANcer Care Equity (ALCANCE) Randomized Controlled Trial: baseline findings from a community health worker led intervention

9:27 - 9:33 AM - Poster:

  • COMPARISON OF SET-UP ERRORS IN CONFORMAL RADIOTHERAPY OF CARCINOMA CERVIX USING DIFFERENT IMMOBILIZATION TECHNIQUES- A PROSPECTIVE STUDY FROM A TERTIARY CARE HOSPITAL IN EASTERN INDIA
  • Factors affecting utilization of chemotherapy in Acute Lymphoblastic Leukemia (ALL): A SEER database study

9:33 - 9:39 AM - Poster: 

  • Healthcare Costs and Financial Barriers to Diagnosis and Treatment of People Living with HIV-Associated Kaposi’s Sarcoma in Western Kenya: A Qualitative Analysis
  • FACTORS INFLUENCING THE ACCEPTANCE OF BREAST CONSERVING SURGERY IN EARLY BREAST CANCER PATIENTS IN RURAL SOUTHERN INDIA - A PROSPECTIVE STUDY

9:39 - 9:45 AM - Poster:

  • Stigma in the Diagnosis and Treatment of HIV-associated Kaposi's Sarcoma
  • Barriers and facilitators to genomic testing uptake and cancer clinical trial enrollment in historically underrepresented patient populations – Clinician and research staff perceptions

Session 2: 9:45 - 11:00 AM PST: Clinical Trials and Disparities in cancer care

Moderator: Chadi Nabhan, MD, MBA, FACP

9:45 - 10:00 AM PST: Keynote speech - Joseph Unger, PhD, MS

10:00 - 11:00 AM PST: Panel discussion - Mark Pegram, MD, Shilpen Patel, MD, Mark Lewis, MD


Session 3: 11:05 AM to 12:05 PM PST: Precision oncology/cellular therapies and cancer disparities

Moderator: Vivek Subbiah, MD

11:05 - 11:15 AM PST: Globalization of Precision Oncology: Future outlook and challenges - Vivek Subbiah, MD

11:15 - 11:25 AM PST: Implementation of Precision medicine in Lung Cancer: Challenges - Rafael Santana-Davila, MD 

11:25 - 11:35 AM PST: Precision Medicine in Bladder Cancer: Challenges and opportunities - Petros Grivas, MD, PhD

11:35 - 11:45 AM PST: Health Economics of Precision Oncology - Dipesh Uprety, MD

11:45 - 11:55 AM PST: Genetics and high risk hereditary cancers and Precision Medicine: Challenges - Marianne Dubard-Gault, MD, MS

11:55 - 12:05 AM PST: Q&A


12:05 - 01:00 PM PST: Lunch & Abstract Session 2

12:05 - 12:15PM - Oral: 

  • Disparities in breast cancer genomic signature ordering practices in the United States

12:15 - 12:25 PM - Oral: 

  • National Coalition for Cancer Survivorship's State of Survivorship Survey: Disparities in Quality of Care

12:25 - 12:35 PM - Oral: 

  • Assessing disparities in social determinants of health between Hispanics/LatinX and Non-Hispanic Whites

12:35 - 12:41 PM - Poster: 

  • Barriers and facilitators to genomic testing uptake and cancer clinical trial enrollment in historically underrepresented patient populations – Clinician and research staff perceptions
  • Delaying Filgrastim Administration after Autologous Stem Cell Transplant in Patients with Multiple Myeloma

12:41 - 12:47 PM- Poster: 

  • Disparity of race reporting and representation among US FDA approved tyrosine kinase inhibitors
  • EVALUATION OF THE PALLIATIVE PROGNOSTIC INDEX (PPI) IN CANCER PATIENTS

12:47 - 12:53 PM - Poster: 

  • Predict score and luminal localized breast cancer in young women
  • Epidemiological and clinical characteristics of male breast cancer in the southern of Tunisia: A single center experience

Session 4: 1:00 - 2:00 PM PST: Plenary lecture - Expediting adoption of practice-changing research in community practice - current challenges and potential solutions

Moderator: Shaji Kumar, MD

Plenary Speaker 1: 

Introduction: Natasha Hunter, MD

Speaker: Nancy E. Davidson, MD

Plenary Speaker 2: 

Introduction: Aparna Parikh, MD, MS

Speaker: Wui-Jin Koh, MD

Panelists: Edward L. Briercheck, MD, Tony Blau, MD


2:00 - 2:15 PM PST: Break


Session 5: 2:15 - 3:30 PM PST: Imaging in LMIC

Moderator: Saurabh Jha, MD

Panelists: Farouk Dako, MD, MPH, Ravi Shrestha, PhD, Chiranjiv Singh, Norissa Haynes, MD, MPH

Grand Hyatt Seattle
721 Pine St
Seattle, WA 98101
United States

Hotel Room Reservation

A limited number of rooms have been reserved for the attendees of this conference at the Grand Hyatt Seattle at the discounted rates listed below. All reservations must be made by Friday, April 8, 2022 to receive the discounted rate. Please follow the link below to reserve your room: https://www.hyatt.com/en-US/group-booking/SEAGH/G-BINY

Name changes on, or other transfers of, room reservations will not be accepted after the Cut-Off Date. The Guest Room Rates are quoted exclusive of any applicable taxes taxes (which are currently 15.7% and $2 nightly Seattle Tourism Assessment Fee) applicable service fees, and/or Hotel-specific fees in effect at the time of the Event. 

Grand Hyatt Seattle is located conveniently in downtown Seattle within walking distance to Space Needle, Pike Place Market, and the shopping district. Take advantage of public transportation when you stay at the Grand Hyatt.
 

 

Travel

Grand Hyatt Seattle is located conveniently in downtown Seattle within walking distance to Space Needle, Pike Place Market, and the shopping district. Take advantage of public transportation when you stay at the Grand Hyatt.
 

TRANSPORTATION
Distance from Seattle-Tacoma International Airport: 15 miles.

The following transportation options are available from/to the airport.

  • Taxi – 25 minutes (estimated $50.00 each way)
  • Scheduled Airport Shuttles – 30 minutes (estimated $35.00 each way)
  • Uber/Lyft – 25 minutes (estimated $30.00 each way)
  • Link Light Rail – 40 minutes ($3.00 each way) - *Exit at Westlake Station, Grand Hyatt is 2 blocks southwest.

PARKING
The hotel offers convenient parking for guests and visitors. The hotel parking options include valet or self parking:
• Valet Parking: $55/night; No In & Out privileges included
• Self-Parking: $37/night; No In & Out privileges included

You can also self park at the nearby Hyatt Regency at $18/night with in/out privileges included.

Amy Davidoff, PhD, MS has a financial relationship (Independent contractor) with Amgen.

Rachel Yung, MD has no relevant financial relationships to disclose at this time.

Bridgette Hempstead has no relevant financial relationships to disclose at this time.

Petros Grivas, MD, PHD has a financial relationship (Independent contractor) with Merck, Bristol-Myers Squibb, AstraZeneca, EMD Serono, Seattle Genetics, Pfizer, Janssen, Mirati Therapeutics, Exelixis, Roche, Genentech, Dyania Health, Infinity Pharmaceuticals, QED Therapeutics, 4D Pharma PLC, Regeneron Pharmaceuticals, Astellas Pharma, Guardant Health, Urogen pharma, Gilead Sciences, Silverback Therapeutics; financial relationship (Grant or Contract) with Research funding to the institution: Pfizer, Clovis Oncology, Bavarian Nordic, Bristol-Myers Squibb, Debiopharm Group, Merck, QED Therapeutics, GlaxoSmithKline, Mirati Therapeutics, EMD Serono, G1 Therapeutics, Gilead Sciences.

Richard Goss, MD has no relevant financial relationships to disclose at this time.

Afsaneh Barzi, MD, PHD has no relevant financial relationships to disclose at this time.\

Hannah Linden, MD has a financial relationship (Grant or Contract) with GE, Sanofi, Veru, Zeno, Tolmar.

Moderator(s)

David Aboulafia, MD

has no relevant financial relationships to disclose at this time.

Chandrikha Chandrasekharan, MBBS

has no relevant financial relationships to disclose at this time.

Julie Gralow, MD

has no relevant financial relationships to disclose at this time.

Natasha Hunter, MD

has no relevant financial relationships to disclose at this time.

Shaji Kumar, MD

has a financial relationship (Professional Services) with Consulting/Advisory Board participation: (with no personal payments) Abbvie, Amgen, BMS, Janssen,  Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secure Biotherapeutics and (with personal payment) Oncopeptides, Beigene, Antengene ;.
has a financial relationship (Grant Or Contract) with Research funding for clinical trials to the institution: Abbvie, Amgen, BMS, Carsgen,  Janssen,  ,  Astra-Zeneca, Novartis, Roche-Genentech,  Takeda, Tenebio, Molecular Templates;.

Chadi Nabhan, MD MBA

has no relevant financial relationships to disclose at this time.

Howard (Jack) West, MD, Associate Professor, City of Hope Cancer Center, Los Angeles, CA

has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Regeneron;.
has a financial relationship (Independent contractor) with Mirati;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Genentech/Roche;.
has a financial relationship (Independent contractor) with Takeda;.
Speaker(s)

GHASSAN ABOU-ALFA, MD

has a financial relationship (Independent contractor) with Adicet, Alnylam, Astra Zeneca, Autem, Bayer, Beigene, Berry Genomics, Eisai, Exelixis, Flatiron, Genentech/Roche, Genoscience, Helio, Incyte, Ipsen, Legend Biotech, Merck, Nerviano, QED, Redhill, Servier, Surface Oncology, Therabionics, Vector, Yiviva;.
has a financial relationship (Grant Or Contract) with Arcus, Agios, Astra Zeneca, BioNtech, BMS, Celgene, Flatiron, Genentech/Roche, Genoscience, Incyte, Polaris, Puma, QED, Silenseed, Yiviva;.
has a financial relationship (Independent contractor) with Astra Zeneca, Celgene, Cend, CytomX, Eli Lilly, Merck, Rafael, Silenseed, Sobi;.

Benjamin Anderson, Professor of Surgery and Global Health Medicine

has no relevant financial relationships to disclose at this time.

Ellen Baker, MD, MPH

has no relevant financial relationships to disclose at this time.

C. Anthony Blau

has no relevant financial relationships to disclose at this time.

Sibel Blau, MD

has no relevant financial relationships to disclose at this time.

Edward Briercheck, MD/PhD

has no relevant financial relationships to disclose at this time.

Robert Carlson, MD

has no relevant financial relationships to disclose at this time.

Elizabeth Chiao, M.D., M.P.H.

has no relevant financial relationships to disclose at this time.

Farouk Dako, MD, MPH

has no relevant financial relationships to disclose at this time.

Nancy Davidson, MD

has no relevant financial relationships to disclose at this time.

Johan De Munter, RN, PgCert

has no relevant financial relationships to disclose at this time.

Marianne Dubard-Gault, MD, MS

has no relevant financial relationships to disclose at this time.

Narjust Duma, MD

has a financial relationship (Independent contractor) with Inivata/Neogenomics;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Astrazeneca;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with BI oncology ;.
has a financial relationship (Independent contractor) with Nexus Oncology;.
has a financial relationship (Independent contractor) with BMS;.

JOSEPHINE FELICIANO, MD

has no relevant financial relationships to disclose at this time.

Nazik Hammad, M.D., M.Sc., MEHP, FACP

has no relevant financial relationships to disclose at this time.

Norrisa Haynes, MD, MPH, MSHP

has no relevant financial relationships to disclose at this time.

Geraldine Jacobson, MD, MPH, MBA

has no relevant financial relationships to disclose at this time.

Mark Lewis, M.D.

has a financial relationship (Professional Services) with QED;.
has a financial relationship (Professional Services) with Foundation Medicine;.
has a financial relationship (Professional Services) with Ipsen;.
has a financial relationship (Professional Services) with Natera;.
has a financial relationship (Professional Services) with Medscape;.
has a financial relationship (Professional Services) with HalioDx;.
has a financial relationship (Professional Services) with AstraZeneca/Daiichi Sankyo;.
has a financial relationship (Professional Services) with TerSera;.
has a financial relationship (Professional Services) with Exelixis;.

Ana Maria Lopez, MD, MPH

has no relevant financial relationships to disclose at this time.

Michael Louella, BS

has no relevant financial relationships to disclose at this time.

Manoj Menon, MD, MPH

has no relevant financial relationships to disclose at this time.

Danny Milner, Jr, MD, MSc, MBA

has no relevant financial relationships to disclose at this time.

Edith Mitchell, MD, MACP, FCCP, FRCP

has a financial relationship (Other) with Genentech;.
has a financial relationship (Other) with Astellas;.
has a financial relationship (Other) with SEMA4;.
has a financial relationship (Other) with Amgen;.
has a financial relationship (Other) with Bristol, Myers, Squibb;.
has a financial relationship (Other) with Corvus;.

Chadi Nabhan, MD MBA

has no relevant financial relationships to disclose at this time.

Salim Nganzi, Mr

has no relevant financial relationships to disclose at this time.

Joel Palefsky, MD

has a financial relationship (Professional Services) with Antiva Bioscience;.
has a financial relationship (Stock Options) with Virion Therapeutics;.
has a financial relationship (Professional Services) with Vir Biotechnology;.
has a financial relationship (Professional Services) with Merck and Co;.

Aparna Parikh, MD

has a financial relationship (Other) with C2i genomics;.
has a financial relationship (Other) with Eli Lilly ;.
has a financial relationship (Other) with Roche;.
has a financial relationship (Other) with Pfizer ;.

Manali Patel, MD, MPH, MS

has no relevant financial relationships to disclose at this time.

Shilpen Patel, Shilpen Patel, MD, FACRO FASTRO

has a financial relationship (Employment) with Genentech;.

Mark Pegram, MD

has no relevant financial relationships to disclose at this time.

Joseph Rosales, MD

has no relevant financial relationships to disclose at this time.

Rafael Santana-Davila, MD

has no relevant financial relationships to disclose at this time.

Matthew Schabath, Matthew B. Schabath, PhD

has no relevant financial relationships to disclose at this time.

Ravi Shrestha, Dr Ravi Bickram Shrestha PhD DIC ACGI FFBA

has a financial relationship (Employment) with Canon Medical;.

Rachna Shroff, MD

has a financial relationship (Professional Services) with Taiho;.
has a financial relationship (Professional Services) with Bristol-Myers;.
has a financial relationship (Professional Services) with Novocure;.
has a financial relationship (Professional Services) with Taiho;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Incyte;.
has a financial relationship (Professional Services) with Servier;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with LOXO;.
has a financial relationship (Professional Services) with Seagen;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with QED Therapeutics ;.
has a financial relationship (Professional Services) with Bayer ;.
has a financial relationship (Professional Services) with IMV Inc. ;.
has a financial relationship (Professional Services) with Rafael Pharm.;.
has a financial relationship (Professional Services) with Clovis ;.
has a financial relationship (Professional Services) with Zymeworks;.
has a financial relationship (Professional Services) with Exelixis ;.
has a financial relationship (Professional Services) with NUCANA;.
has a financial relationship (Professional Services) with Boehringer Ingelheim;.
has a financial relationship (Professional Services) with Merck;.

Chiranjiv Singh

has a financial relationship (Employment) with Qure.ai Technologies Inc;.

Bhawna Sirohi, MBBS, FRCP

has no relevant financial relationships to disclose at this time.

Dingle Spence, MBBS, Dip Pall Med, FRCR

has no relevant financial relationships to disclose at this time.

Vivek Subbiah, MD

has a financial relationship (Grant Or Contract) with Blueprint Medicines;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Grant Or Contract) with LOXO/ Eli Lilly;.
has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Grant Or Contract) with Relay Therapeutics;.
has a financial relationship (Grant Or Contract) with Novartis;.

Richard Sullivan

has no relevant financial relationships to disclose at this time.

Lisa Tachiki, MD

has no relevant financial relationships to disclose at this time.

Molly Tokaz

has no relevant financial relationships to disclose at this time.

Joseph Unger

has no relevant financial relationships to disclose at this time.

Dipesh Uprety, MD, FACP

has a financial relationship (Professional Services) with Daiichi Sankyo, Astrazeneza, and Sanofi.;.

Everett Vokes, MD

has a financial relationship (Financial Support) with Beigene;.
has a financial relationship (Financial Support) with Genentech;.
has a financial relationship (Financial Support) with AstraZeneca;.
has a financial relationship (Financial Support) with EMD Serono;.
has a financial relationship (Financial Support) with Novartis;.
has a financial relationship (Financial Support) with AbbVie;.
has a financial relationship (Financial Support) with Eli Lilly;.
has a financial relationship (Financial Support) with Merck;.
has a financial relationship (Financial Support) with BioNTech;.
has a financial relationship (Financial Support) with GlaxoSmithKline;.

Michael Wagner, M.D.

has a financial relationship (Independent contractor) with Epizyme;.
has a financial relationship (Independent contractor) with Deciphera;.
has a financial relationship (Independent contractor) with Adaptimmune;.

Howard (Jack) West, MD, Associate Professor, City of Hope Cancer Center, Los Angeles, CA

has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Genentech/Roche;.
has a financial relationship (Independent contractor) with Takeda;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Regeneron;.
has a financial relationship (Independent contractor) with Mirati;.

Siddhartha Yadav, Siddhartha Yadav, MD, FACP

has no relevant financial relationships to disclose at this time.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT 

This activity is supported with independent medical education grants from the following companies:

  • Novartis Pharmaceuticals.

  • Janssen Scientific Affairs, LLC

  • Pfizer, Inc.

  • Merck Sharp & Dohme

  • AstraZeneca 

BCRF Sponsorship

We would like to thank the Breast Cancer Research Foundation for sponsoring the Breast Cancer Disparities Session.

Available Credit

  • 14.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 14.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 14.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 14.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 14.00 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

Price

Cost:
$450.00
Please login or register to take this course.

Notice to HCPs employed by the industry:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again. 

Registration fees for SCHD22 increase on 4/15/22. Late registration fees apply.

Cancellation Policy

Refund Policy 

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is cancelled six weeks before the conference.
  • No refunds will be issued if registration is cancelled after that date.  

No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.